SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

Partial epigenetic reprogramming of adult tissue

Transiently expressing reprogramming factors (OCT4, SOX2, KLF4) in adult cells to reset age-associated gene expression without erasing cell identity.

State of the art

Life Biosciences ER-100 (AAV-delivered OSK switched on by oral doxycycline) dosed its first patient in June 2026 and reported interim tolerability in three glaucoma patients in October 2026, following nonhuman-primate NAION studies.

What’s blocking it
  • Dose and duration window is narrow - too much OSK expression causes loss of cell identity and teratoma risk
  • Doxycycline-gated expression gives coarse control over how far each cell is rewound
  • No delivery route demonstrated for simultaneous reprogramming of many tissues in one body

Who’s working on it

  • Received FDA clearance in January 2026 and dosed the first patient in its ER-100 OSK Phase 1 (NCT07290244); closed an 80 million dollar Series D in April 2026

  • Altos LabsStartup

    Launched in 2022 with 3 billion dollars to pursue reprogramming-based rejuvenation; its 2024 and 2025 papers extended lifespan in progeria mice and reversed mesenchymal drift

  • Juan Carlos Izpisua BelmonteResearcher
    Altos Labs

    Pioneered cyclic in vivo partial reprogramming and reported Cdkn2a-promoter-gated OSK extending mouse lifespan without increased tumour occurrence (2024)

  • David SinclairResearcher
    Harvard Medical School

    His OSK optic-nerve rejuvenation work is the basis of Life Biosciences ER-100, the first partial-reprogramming therapy dosed in humans

  • Universidad Catolica San Antonio de MurciaAcademic lab

    Co-funded and co-authored the Altos targeted partial reprogramming study published in Science Translational Medicine in 2024

What to invest in

KindInvestmentScale
researchDose-response and tumorigenicity studies of multi-tissue reprogramming in nonhuman primates, with cell-identity readouts$$$ $100M – $1B
engineeringTighter expression switches (small-molecule or circuit-gated) giving per-cell control of reprogramming depth$$ $10M – $100M

Sci-fi concepts in reach

Whole-body rejuvenation treatmentdirect

Sources